{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-368288","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2026-08-26T20:05:16+00:00","discovered_at":"2026-08-26T20:06:31.608030+00:00","generated_at":"2026-08-26T20:06:48.493199+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"LeonaBio enrolls 500th subject in Phase 3 ELAINE-3 trial; triggers warrant exercise","bullets":["Enrolled 500th subject in Phase 3 ELAINE-3 trial (NCT05696626) for lasofoxifene + abemaciclib in ER+/HER2- ESR1-mutated metastatic breast cancer.","Milestone triggers exercisability of 23,031,494 Series A Common Warrants at $6.35/share from Dec 2025 private placement.","Full exercise would raise ~$146.2M; warrants expire 30 days after initial exercise date, no later than Nov 30, 2026.","Warrants exercisable cash or cashless if resale registration unavailable; initial exercise date set as of Aug 26, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-368288","json":"https://secwatch.observer/filing/0001193125-26-368288.json","markdown":"https://secwatch.observer/filing/0001193125-26-368288.md","text":"https://secwatch.observer/filing/0001193125-26-368288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526368288/0001193125-26-368288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000119312526368288/lona-20260826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-26T20:06:48.493199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}